Year All20242023202220212020201920182017201620152014 Abivax Provides Operational and Key Program Update July 15, 2024 Read More Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting June 04, 2024 Read More Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 May 08, 2024 Read More Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents May 07, 2024 Read More Abivax publishes financial reports with the French and U.S. securities regulatory agencies April 05, 2024 Read More Abivax reports 2023 financial results and operational update April 02, 2024 Read More Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) February 13, 2024 Read More Abivax appoints Ana Sharma as Vice President, Global Head of Quality February 07, 2024 Read More Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease February 02, 2024 Read More Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 January 24, 2024 Read More
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting June 04, 2024 Read More
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 May 08, 2024 Read More
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents May 07, 2024 Read More
Abivax publishes financial reports with the French and U.S. securities regulatory agencies April 05, 2024 Read More
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) February 13, 2024 Read More
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease February 02, 2024 Read More
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 January 24, 2024 Read More
